Scott Kratz recently joined the Global Leadership Panel of Fight Cancer Global (FCG). Scott joined FCG to be a resource and advise in the area of clinical trials and patient recruitment.

Here is background on FCG:

  1. They are fighting cancer by working to transform the global cancer ecosystem. Their goal is to develop a comprehensive, 360-degree approach to battle cancer. They want to unite people fighting the disease by crossing geographic, socioeconomic and functional boundaries. They believe this approach creates a patient-centric community for all players, through global engagement and collaboration.
  2. They want to empower the 3.5 million cancer patients and survivors FCG touches. And they want to streamline the information flow for all entities involved—Hospitals, Researchers, Pharmaceuticals, Governments, Academic Institutions, Non-profits and Advocacy Groups. There are many luminaries that are part of the organization. More on that here.
  3. FCG has more than 100 global partners – India, China, Europe, the Middle East and North America.

[FCG] is fighting cancer by working to transform the global cancer ecosystem. Their goal is to develop a comprehensive, 360-degree approach to battle cancer. … They believe this approach creates a patient-centric community for all players, through global engagement and collaboration.

Much Work to Do
Although cancer deaths have decreased recently in the U.S., there is more work to do to globally. Cancer worldwide is:

  • A significant issue.
    Cancer causes about 1 in every 6 deaths worldwide–more than AIDS, tuberculosis, and malaria combined.
  • Not abating.
    According to estimates from the International Agency for Research on Cancer (IARC), the global cancer burden is estimated at 18.1 million new cases (a little less than the entire population of Florida) and 9.6 million deaths (just under Michigan’s entire population).
  • Expected to get worse.
    By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths simply due to the growth and aging of the population.

Scott said that speaking with CEO VJ Kondur was the final deciding factor to join. “He and I discussed what can be done to get more patients involved in oncology clinical trials worldwide. He listened, was engaging, and we found many areas of collaboration, especially around patient identification, trial design, and clinical site feasibility. Their mission maps well with how Inteliquet wants to improve the process of clinical research. Helping providers and their patients with more choices and options to help battle cancer and not feel alone is a mission that we want to be a part of.”

While it is still early in the relationship, Scott believes there will be more to discuss in the near future, such as international projects FCG is planning in Africa.

In the meantime, learn more about Fight Cancer Global here.